Matthew Roden, Ph.D.

Dr. Matthew Roden is the CEO of HotKnot Therapeutics, an MPM portfolio company. Matt serves on the board of iTeos Therapeutics (NASDAQ: ITOS) and as chairman of the board of Turmeric Acquisition Corp, both MPM portfolio companies.

Prior to joining MPM, Matt’s career spanned senior leadership in large pharma, the healthcare equity capital markets, and in basic science as an immunologist and structural biologist. Most recently, Matt was Senior Vice President and Head of Enterprise Strategy at Bristol Myers Squibb (BMS). In this role, Matt delivered the initial strategic plan for the company following its acquisition of Celgene. Earlier, he served as Head of Strategic Corporate Development, accountable for mergers and acquisitions, structured transactions, strategic equity investing, and divestitures, as well as Head of Global BD Assessment, leading business development search and evaluation activities for all therapeutic categories. Matt served on the R&D Leadership Team representing external innovation and led teams on over 100 business development transactions that are cumulatively valued at over $125 billion, including BMS’ acquisition of Celgene, the largest acquisition in the healthcare industry to date.

Before joining BMS, Matt was Head of Biotechnology Equity Research at UBS Investment Bank. Earlier, he was a Senior Equity Analyst covering biotechnology at J.P. Morgan and Bank of America Merrill Lynch, and was an Associate at Credit Suisse First Boston. In addition to his research coverage of the entire biotech sector, Matt and his teams provided equity research diligences and investor engagement on 24 Initial Public Offerings totaling $3.3bn in initial value from 2005-2016. Matt has also served in advisory or Board capacities to several organizations, including biotechnology companies, investment funds, BIO, BioNJ, and the State of New Jersey.

Matt earned his Ph.D. from the Albert Einstein College of Medicine, focusing on the structural biology of immune-relevant molecules. His graduate work was preceded by his pre-doctoral clinical research fellowship in immuno-oncology at the National Cancer Institute in Bethesda, Maryland. Matt received  a M.S. degree from Georgetown University and a B.S. from George Mason University.

Jon Wigginton, M.D.

Dr. Jon Wigginton currently serves as an MPM Advisor and CMO of Cullinan Oncology, an MPM portfolio company that focuses on developing high-value cancer therapeutics using a novel, scalable business model.

Prior to MPM, Jon served as the CMO at MacroGenics (NASDAQ:MGNX), where he led the company’s evolution of a fully-integrated, clinical-stage cancer immunotherapy organization. This included the translation of ten new molecules into the clinic, including early phase and/or proof-of-concept studies with bispecific molecules, checkpoint inhibitors, Fc-optimized antibodies and antibody drug conjugates, as well as the design and execution of registration-directed studies. Previously, he served as the Therapeutic Area Head, Immuno-Oncology, Early Clinical Research at Bristol-Myers Squibb (NYSE: BMY). There, he oversaw early clinical development of the BMS Immuno-Oncology portfolio including anti-PD-1, anti-PD-L1 and the anti-PD-1/anti-CTLA-4 combination program among others. He also co-led the BMS International Immuno-Oncology Network.

During his academic career, Jon served as Head of the Investigational Biologics Section, Center for Cancer Research, NCI, where he led an integrated basic, translational and clinical research effort focused on combination immunotherapy in preclinical models and early clinical studies. He also served previously as president of the Society for Immunotherapy of Cancer (SITC).

Jon received his M.D. and B.S. in Biology, with distinction, from the University of Michigan.

Andrew M. Scharenberg, M.D.

Dr. Andrew M. Scharenberg is the founder and CEO of Umoja Biopharma, an MPM portfolio company. Prior to founding Umoja, Andrew was an Attending Physician at Seattle Children’s Hospital, a Professor in the Department of Pediatrics, and an Adjunct Professor in the Department of Immunology at the University of Washington School of Medicine in Seattle.

While at Seattle Children’s/UW, Andrew co-directed the Program in Cell and Gene Therapy at Seattle Children’s Research Institute, working to translate cell and gene therapies for the treatment of inherited immunologic and blood diseases. This work led to the development of a program in engineered regulatory T-cells, partnered with Casebia Therapeutics for the purpose of developing a gene edited cell therapeutic for Type I diabetes and other inflammatory diseases. Previously, he was  the Chief Scientific Officer of Cellectis Therapeutics, where he initiated the development of an allogeneic CAR T-cell platform, and co-founder of Pregenen Inc., a gene editing and cell-signaling technology company that was acquired by bluebird bio in 2014. He also serves on the scientific advisory boards of Alpine Immune Sciences (chair), Generation Bio (chair), Genti Bio (chair), and Tessera Therapeutics.

Andrew earned his M.D. from the University of North Carolina School of Medicine, and then completed residency at the University of North Carolina Children’s Hospital and his fellowship in immunology at NIH and at the Division of Experimental Pathology, Beth Israel Hospital. Andrew received the American Pediatric Society/Society for Pediatric Research National Young Investigator Award in 2002. He is an active member of the American Society for Clinical Investigation and the American Pediatric Society.

Thomas M. Barnes, Ph.D.

Dr. Thomas (Tom) M. Barnes is the CEO of Orna Therapeutics, an MPM portfolio company.  Tom is a veteran entrepreneur who has turned creative scientific visions into successful businesses for both startups and established organizations, having led platform-based research and drug discovery teams for over 20 years.  Tom has co-founded or helped launch several companies, including Intellia Therapeutics and Eleven Biotherapeutics.

Prior to joining MPM, Tom was the Chief Scientific Officer of Intellia Therapeutics (NASDAQ: NTLA). During his tenure there, he built and established the discovery team, and helped raise over $300M over several financings, including Intellia’s IPO. He also led efforts to extend the reach of Intellia’s CRISPR platform into ex vivo delivery. He played a significant role as the main corporate spokesperson to lay and industry press, and to governmental and non-governmental organizations on the rapidly evolving and intensely followed CRISPR landscape.

Tom has wide-ranging knowledge of biological systems through his work across diverse platforms, including gene editing, genomics and gene discovery, small molecule drug repositioning, and protein engineering. Previously, as Vice President of Discovery at Eleven Biotherapeutics, Tom built the and led the research team in creating a novel chimeric cytokine antagonist, as well as novel half-life extension technologies for systemic and topical application. As Senior Vice President and site head of GeneLogic’s drug repositioning division, he oversaw technology platforms in metabolomics, toxicogenomics, gene expression informatics, and the genetics of drug metabolism and transport.

Tom received his Ph.D. from the University of Cambridge, and completed research fellowships at Harvard Medical School and McGill University.

Scott Chappel, Ph.D.

Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held several senior leadership roles in companies developing novel therapies in oncology and other areas. Scott also serves as a Scientific Advisor to MPM portfolio company iTeos Therapeutics (NASDAQ: ITOS).

Prior to joining MPM, Scott was a founder and Chief Technology Officer at Surface Oncology, where he oversaw all antibody generation, engineering, production, characterization and manufacturing as well as all preclinical IND-enabling studies. He was also a founder and CSO at Arteaus Therapeutics which developed an antibody for the prevention of migraine headaches (acquired by Eli Lilly) and Tokai Pharmaceuticals, where he worked to develop an oral therapeutic for the treatment of prostate cancer. Prior to Tokai, he held roles as a Senior Vice President of Research at Dyax and as a Chief Scientist at Serono.

Scott has authored or co-authored more than 65 peer-reviewed scientific publications and been named inventor on 24 issued U.S. patents. He received his Ph.D. in Neuroscience from the University of Maryland School of Medicine.

Detlev Biniszkiewicz, Ph.D.

Dr. Detlev Biniszkiewicz is President and CEO of two early-stage MPM portfolio companies, Rekindle Therapeutics and NextPoint Therapeutics. Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role at MPM. Detlev is also a board member of iTeos Therapeutics (NASDAQ: ITOS) and Maverick Therapeutics, also MPM portfolio companies.

Prior to joining MPM, Detlev was the President and CEO of Surface Oncology (NASDAQ: SURF), where he led its growth and transformation through to clinical-stage and its preparation for a public offering. Prior to Surface Oncology, he was Vice President of Strategy in AstraZeneca’s Oncology Unit and was part of the oncology leadership that developed Lynparza® and Tagrisso®, two innovative medicines that help thousands of patients suffering from cancer. His group transformed AstraZeneca’s Oncology pipeline through numerous licensing deals, clinical and academic collaborations, and external research. Detlev has also held multiple roles at Novartis including Global Head of Portfolio, where his group provided oversight of Novartis’ research and early development portfolio.

Detlev began his career at the Boston Consulting Group and performed his academic research at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology.

David Hallal

David Hallal currently serves as an MPM Advisor and CEO of ElevateBio, an MPM portfolio company that is developing a portfolio of cell and gene therapy subsidiaries to treat cancer and other incurable diseases. He is also CEO of AlloVir (NASDAQ: ALVR), an ElevateBio portfolio company developing innovative allogeneic, off-the-shelf, multi-virus specific T-cell immunotherapies.

David brings nearly 30 years of senior executive leadership experience in growing and operating several successful biotechnology companies to his role at MPM. He also serves as Chairman of the Board at iTeos Therapeutics (NASDAQ: ITOS), an MPM portfolio company, and Scholar Rock, and is a member of the Board of Directors at Seer.

Prior to MPM, he spent more than 10 years at Alexion Pharmaceuticals where he played a central role in transforming the then pre-commercial company into a successful commercial company with more than $3 billion in annual revenues. As the CEO of Alexion, he expanded the pipeline from a single-product to a multi-product enterprise and was responsible for overseeing key product development milestones including the highly successful launch of Strensiq® and the rapid 18-month advancement of Alexion’s highest value pipeline candidates from preclinical to registration trials for multiple diseases. Prior to his appointment as CEO, he served as Alexion’s Chief Operating Officer and then its Chief Commercial Officer and built the company’s commercial infrastructure and a 50-country operating platform to support the launch of Soliris® for the treatment of Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome, which resulted in the successful commercialization of an ultra-orphan drug in the biotechnology industry. Prior to Alexion, he held commercial leadership positions at Amgen, Biogen and Eyetech Pharmaceuticals where he was responsible for the launch and adoption of first-in-class products in hematology, oncology, nephrology, immunology, and ophthalmology.

David received his B.A. in Psychology from the University of New Hampshire.

Owen Hughes

Owen Hughes currently serves as an MPM Advisor and CEO of Cullinan Management (NASDAQ: CGEM), an MPM portfolio company that focuses on developing high-value cancer therapeutics using a cost-efficient business model.

Prior to MPM, Owen served as the Chief Business Officer and Head of Corporate Development at Intarcia Therapeutics, where he was responsible for financing, M&A, business development and operations. Prior to Intarcia, he served as a Director of Brookside Capital, a hedge fund under the Bain Capital umbrella, managing public and private healthcare investments. Prior to his tenure at Brookside, Owen was Senior Portfolio Manager at Pyramis Global Advisors, a Fidelity Investments Company. He has more than 16 years of Wall Street experience, on both the buy- and sell-side. Owen is currently a director of Radius Health and Translate Bio.

Owen received his B.A. from Dartmouth College

Leigh Zawel, Ph.D.

Dr. Leigh Zawel is the CSO of Small Molecules for Cullinan Oncology (NASDAQ: CGEM), a portfolio company of the UBS Oncology Impact Fund managed by MPM. Leigh is an oncology expert with significant pharmaceutical experience overseeing large and small-molecule projects He is also a Board Member of Rekindle Therapeutics, an MPM Capital portfolio company.

Prior to joining MPM, Leigh was Vice President and East Coast Site Head for Pfizer’s Centers for Therapeutic Innovation where he managed a portfolio of large and small-molecule projects spanning oncology, immunology and rare disease from which five clinical stage programs emerged in five years. Prior to Pfizer, he was the oncology site lead at Merck Research Laboratories in Boston. In this role, he was responsible for drug discovery efforts focused on the identification of development candidates for programs in the oncology franchise. He also formerly held posts at Sanofi-Aventis, where he was Director of Cancer Biology, and at Novartis Institutes for Biomedical Research, where he was an Oncology Group Leader and led the team credited with discovering LCL161, an industry leading IAP inhibitor. He has a deep background in identifying and validating oncology drug targets and in transitioning drug discovery programs through lead optimization to Phase 1 clinical trials. Leigh has published more than 35 scientific papers. He is also an inventor on 45 patents covering chemical matter, drug combinations, biomarker utility and gene function in areas of apoptosis, inflammation and TGFB signaling.

Leigh earned his Ph.D. in the laboratory of Danny Reinberg where he identified and characterized components of the RNA Polymerase II basal transcription machinery. His postdoctoral training was in the laboratory of Bert Vogelstein and Ken Kinzler and focused on dysregulation of TGFB signaling in cancer. Leigh also holds a M.S. in Bacteriology from the University of Wisconsin, as well as a B.S. in Biology from Rutgers University.

Thomas Ebeling

Thomas Ebeling currently serves as an MPM Advisor and is the former CEO of ProSiebenSat.1 Media SE and Novartis Pharma. He currently serves on the supervisory board of Bayer AG and as the Chairman of Sivantos (Hearing Aids), Apleona (Facility Managment) and Remagine Ventures (Media and E Commerce). He is also a former board member of Lonza AG.